Seres Therapeutics (NASDAQ:MCRB) Lowered to “Sell” Rating by Wall Street Zen

Seres Therapeutics (NASDAQ:MCRB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $14.33.

Seres Therapeutics Trading Up 3.0%

Shares of NASDAQ:MCRB opened at $8.47 on Friday. The firm has a market cap of $76.65 million, a price-to-earnings ratio of -2.37 and a beta of 0.22. The stock’s 50-day moving average price is $15.06 and its two-hundred day moving average price is $16.77. Seres Therapeutics has a 12-month low of $6.53 and a 12-month high of $29.98.

Hedge Funds Weigh In On Seres Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp boosted its position in Seres Therapeutics by 14.0% during the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 4,170 shares during the period. Vontobel Holding Ltd. raised its position in Seres Therapeutics by 4.8% in the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 4,723 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Seres Therapeutics during the fourth quarter worth about $213,000. Geode Capital Management LLC boosted its position in shares of Seres Therapeutics by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after buying an additional 1,160 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after buying an additional 5,157 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.